Patents Examined by Yih-Horng Shiao
-
Patent number: 11826377Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.Type: GrantFiled: November 17, 2021Date of Patent: November 28, 2023Assignee: Vymedic, LLCInventors: Kenneth E. Phillips, Cynthia A. Winning
-
Patent number: 11819040Abstract: Methods for providing dietary calcium to livestock and other animals and the compositions for use in providing dietary calcium to livestock are disclosed. Kits to provide the animal with a desired amount of supplemental calcium during normal watering is also disclosed.Type: GrantFiled: December 19, 2018Date of Patent: November 21, 2023Assignee: DSM IP ASSETS B.V.Inventors: Aaron Cowiesen, Jose-Otavio Sorbara
-
Patent number: 11821037Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.Type: GrantFiled: February 27, 2020Date of Patent: November 21, 2023Assignee: THE SCRIPPS RESEARCH INSTITUTEInventors: Daniel R. Salomon, Sunil M. Kurian, Steven R. Head
-
Patent number: 11814621Abstract: Disclosed are methods, systems, components, and compositions for synthesis of sequence defined polymers. The methods, systems, components, and compositions may be utilized for incorporating novel substrates that include non-standard amino acid monomers and non-amino acid monomers into sequence defined polymers. As disclosed herein, the novel substrates may be utilized for acylation of tRNA via flexizyme catalyzed reactions. The tRNAs thus acylated with the novel substrates may be utilized in synthesis platforms for incorporating the novel substrates into a sequence defined polymer.Type: GrantFiled: June 3, 2019Date of Patent: November 14, 2023Assignees: Northwestern University, The Board of Trustees of the University of IllinoisInventors: Michael Christopher Jewett, Joongoo Lee, Jeffrey S. Moore, Kenneth E. Schwieter, Kevin Jerome Schwarz
-
Patent number: 11815435Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.Type: GrantFiled: February 23, 2018Date of Patent: November 14, 2023Assignee: HiberCell, Inc.Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
-
Patent number: 11813276Abstract: Provided herein are methods to improve transport or uptake of an avermectin compound in a cell or tissue expressing an efflux transporter P-glycoprotein (Pgp) by co-administering an effective amount of the avermectin compound and a Ppg inhibitor to the cell or tissue. The method also provides improved efficiency transport or uptake of an avermectin compound in the cell or tissue. The methods can be used therapeutically to treat Alcohol Use Disorder.Type: GrantFiled: October 21, 2021Date of Patent: November 14, 2023Assignee: University of Southern CaliforniaInventor: Daryl Davies
-
Patent number: 11813272Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.Type: GrantFiled: November 17, 2020Date of Patent: November 14, 2023Assignee: Flagship Pioneering Innovations V, Inc.Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
-
Patent number: 11806459Abstract: This invention teaches a targeted apheresis method of treating a pregnant woman with preeclampsia, or who is predisposed to developing preeclampsia, utilizing immobilized binding agents contained within an apheresis device to remove sVEGFR-1 and sVEGFR-2, and one or more other harmful factors associated with preeclampsia selected from a list that includes: sEndoglin, Endothelin-1, TNF, IL-1, IL-6, IL-12, IL-18, digitalis-like factor, ouabain-like factor, marinobufagenin, .marinobufotoxenin, and telocinobufagin. The binding agents used are antibodies or aptamers or binding peptides. Reducing the concentration of sVEGFR-1, sVEGFR-2 and other harmful factors in the pregnant woman's blood using targeted apheresis will alleviate or delay the symptoms of preeclampsia, and thus postpone premature delivery of the baby so that the baby is born at term or as close to term as possible.Type: GrantFiled: January 16, 2021Date of Patent: November 7, 2023Inventor: Henry J. Smith
-
Patent number: 11801325Abstract: The invention is directed to a multi-arm tissue-adhesive polymer wherein at least six or more arms each comprise a reactive functional group that can form a urethane or a urea bond with an amine group present in tissue, as well as to the use thereof for sealing or closing of tissue and use in a medical treatment of a human or animal body. In a further aspect, the invention is directed to a method for the preparation of said multi-arm tissue-adhesive polymer.Type: GrantFiled: October 1, 2018Date of Patent: October 31, 2023Assignee: Polyganics IP B.V.Inventors: Martin Franke Tooren, Justin Van Der Veen, Dirk Erik Muller
-
Patent number: 11791015Abstract: An analyzer includes a separation data holding part, a determination criterion holding part, and a component peak determination part. The separation data holding part retains, as reference data, separation data obtained by an electrophoresis analysis for a reference sample including a reference component which is a known component and retains, as data to be analyzed, separation data obtained by an electrophoresis analysis for a sample to be analyzed. The determination criterion holding part retains a determination criterion for determining whether a component peak in the reference data and a component peak in the data to be analyzed are identical. The component peak determination part is configured to determine whether the component peak in the reference data and the component peak in the data to be analyzed are identical to each other, using the determination criterion.Type: GrantFiled: December 6, 2019Date of Patent: October 17, 2023Assignee: SHIMADZU CORPORATIONInventors: Kota Ogino, Akira Harada, Hidesato Kumagai
-
Patent number: 11786541Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.Type: GrantFiled: August 13, 2021Date of Patent: October 17, 2023Assignee: RedHill Biopharma Ltd.Inventors: Reza Fathi, Dror Ben-Asher, Guy Goldberg
-
Patent number: 11786542Abstract: Disclosed are methods and compositions for treating proliferative cell diseases and disorders such as cancers. Particularly disclosed are methods and composition for treating cancers such as glioblastoma by administering a therapeutic agent that alters the pathways used for purine biosynthesis by inhibiting the biological activity of ARL13B and/or IMPDH proteins in conjunction with additional therapeutic agents such as alkylating agents.Type: GrantFiled: November 13, 2020Date of Patent: October 17, 2023Assignee: Northwestern UniversityInventors: Atique U. Ahmed, Jack M. Shireman, Cheol H. Park
-
Patent number: 11782050Abstract: The present disclosure relates to, inter alia, cell-based assays, recombinant cell lines, and methods for quantifying the potency and efficacy of cannabinoids and/or terpenoids.Type: GrantFiled: September 18, 2018Date of Patent: October 10, 2023Assignee: CannaMetrix, LLCInventor: Harold C. Smith
-
Patent number: 11781191Abstract: Oligonucleotides for use in amplifying at least one gene present in M. riyadhense are disclosed. The oligoncleotides include forward primers, SEQ ID NO:1, 3, 5, and 7 and the reverse primers comprises, consists essentially of or consists of SEQ ID NO:2, 4, 6, and 8, fragment(s), derivative(s), mutation(s), or complementary sequence(s) thereof. Also provided are methods for detecting the presence of M. riyadhense in a sample. The method includes contacting a biological sample with a pair of forward/reverse primers, under conditions suitable for amplification of at least one gene product from M. riyadhense if present in a sample and detecting the presence of the amplification product. The oligonucleotides and method disclosed herein can be used to determine the presence of M. riyadhense in a biological or non-biological sample. The sample can be obtained from a subject such as a human subject.Type: GrantFiled: August 8, 2020Date of Patent: October 10, 2023Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Arnab Pain, Qingtian Guan
-
Patent number: 11771688Abstract: Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.Type: GrantFiled: June 24, 2019Date of Patent: October 3, 2023Assignee: AMPLYX PHARMACEUTICALS, INC.Inventors: Andrei W. Konradi, Jonathan A. Covel, Michael Grey
-
Patent number: 11766450Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.Type: GrantFiled: March 8, 2021Date of Patent: September 26, 2023Assignee: PT. Sahabat Lingkungan HidupInventors: Peter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
-
Patent number: 11751573Abstract: A composition derived or derivable from seaweed is provided. The composition comprises one or more plant hormones; and/or one or more acidic polysaccharides. Also provided is a method for producing a composition, including the step of extracting one or more agents from seaweed. A method of stimulating plant growth by applying a composition derived or derivable from seaweed is also provided.Type: GrantFiled: November 16, 2018Date of Patent: September 12, 2023Inventors: Bernard Port-Louis, Benjamin Port-Louis
-
Patent number: 11752166Abstract: Disclosed herein are combination therapies for use in the treatment or prevention of HCV by administering Compound A and a second HCV inhibitor.Type: GrantFiled: May 9, 2019Date of Patent: September 12, 2023Assignee: COCRYSTAL PHARMA, INC.Inventors: Irina C. Jacobson, Biing Yuan Lin, Sam SK Lee
-
Patent number: 11744895Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.Type: GrantFiled: August 6, 2021Date of Patent: September 5, 2023Assignee: AEGIS THERAPEUTICS, LLCInventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
-
Patent number: 11746385Abstract: The present disclosure provides methods of assessing tumor progression in a subject. In an aspect, a method for assessing tumor progression of a subject can comprise: measuring a count of a plurality of cell-free DNA (cfDNA) molecules at each of a plurality of genomic regions, wherein the plurality of cfDNA molecules is obtained or derived from a bodily fluid sample of the subject; processing the counts measured at each of the genomic regions to obtain quantitative measures of deviation of the counts relative to a plurality of reference values, to produce deviation scores; determining a difference between the deviation scores and a plurality of reference deviation scores to produce changes in deviation (CID) values, and calculating a CID score based on the CID values; and detecting a tumor progression of the subject when the CID score satisfies a pre-determined criterion.Type: GrantFiled: May 18, 2020Date of Patent: September 5, 2023Assignee: Lexent Bio, Inc.Inventor: Abhik Shah